Larimar Therapeutics, Inc. (LRMR) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $3.83, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $14.40 vs price $3.82 — ratio 3.8×). Rejected, falling back to technical TP.; Market cap $397M below $400M minimum.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment... Read more
Hold if already holding. Not a fresh buy at $3.83, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $14.40 vs price $3.82 — ratio 3.8×). Rejected, falling back to technical TP.; Market cap $397M below $400M minimum. Chart setup: RSI 54 mid-range, Bollinger mid-band. Market cap $397M below $400M minimum. Not in investable universe. Score 4.6/10, moderate confidence.
Passes 5/9 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $3.83, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $14.40 vs price $3.82 — ratio 3.8×). Rejected, falling back to technical TP.; Market cap $397M below $400M minimum. Chart setup: RSI 54 mid-range, Bollinger mid-band. Market cap $397M below $400M minimum. Not in investable universe. Target $4.23 (+10.4%), stop $3.55 (−7.9%), A.R:R 0.0:1. Score 4.6/10, moderate confidence.
Take-profit target: $4.23 (+10.7% upside). Target $4.23 (+10.4%), stop $3.55 (−7.9%), A.R:R 0.0:1. Stop-loss: $3.55.
DATA_ISSUE: analyst_target_implausible (raw $14.40 vs price $3.82 — ratio 3.8×). Rejected, falling back to technical TP.; Market cap $397M below $400M minimum.
Larimar Therapeutics, Inc. trades at a P/E of N/A (forward -3.2). TrendMatrix value score: 5.0/10. Verdict: Hold.
16 analysts cover LRMR with a consensus score of 4.4/5. Average price target: $14.
What does Larimar Therapeutics, Inc. do?Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases...
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.